Download Curriculum Vitae: Dr Matthew Sperrin

BOWEL DISEASE RESEARCH FOUNDATION
of The Association of Coloproctology of Great Britain and Ireland
APPLICATION FORM FOR THE BDRF OBSERVATIONAL RESEARCH GRANTS
Applications should be a maximum of 4 pages, including any images, and also accompanied by a CV
(1 side of A4) for each applicant. Please send the form with CVs electronically as one single Word
document using 12pt typeface.
1. Name of the investigator
Mr Graham Branagan
2. Job title
Consultant colorectal surgeon
3. Email address
4. Tel. No.
5. Institution
6. Name of supervisor
7. Name of Co-investigators
8. Ordinary member of ACPGBI
9. Title of Project
[email protected]
Work: 01722 336262 ext. 4483
Sponsor: Salisbury NHS Foundation Trust
Collaborator: The Christie NHS Foundation Trust &
University of Manchester (UoM)
Not applicable
Salisbury:
Mr Graham Branagan, Consultant Colorectal Surgeon
Dr Clare Fuller, Consultant Pathologist
Manchester:
Professor Andrew Renehan, Consultant Colorectal Surgeon
Dr Ian Hampson, Lead Scientist, Viral Oncology Group, UoM
Dr Ivona Baricevic-Jones, Post-doctoral scientist, Viral Oncology
Group, UoM
Dr Matthew Sperrin, Lecturer in Biostatistics, UoM
Mr Graham Branagan
HomeR: Development of HPV genotyping as a predictive
biomarker of chemo-radiotherapy response in patients with Rectal
Cancer
12 months
10. Length of project
Funding requested
11.a Total amount
£30,000
11.c How many instalments
Not applicable
11.d In which months instalments
Project start date: 1st February 2014
need to be paid
12. Has the institution administering
funding agreed exemption from overheads ?
Yes

No
Project Details
13. Background to project
Human papilloma virus (HPV) is an established aetiological factor for the development of ano-genital and
oro-pharyngeal cancers, but less appreciated, HPV is also associated with the development of rectal cancer
[1]. Moreover, in ano-genital and oro-pharyngeal cancers, the presence of HPV16, the commonest
oncogenic genotype, is associated with better prognosis and improved response to treatment, mainly chemoradiotherapy (CRT) [2]. A parallel hypothesis has not been tested in rectal cancer.
In the UK, there are approximately 15,000 new cases of rectal cancer per year. Surgery is the
mainstay of treatment. Locally advanced disease is treated initially with ‘downstaging’ pre-operative CRT,
followed by surgery 8 to 15 weeks later, but this combination is associated with considerable peri-operative
mortality and long-term morbidity. In 15% to 20% of cases, CRT may result in complete disappearance of
tumour. In patients without residual tumour on imaging and endoscopy (clinical complete response), a waitand-see policy (omission of surgery with follow-up) might be considered an alternative to major resection 1
and represents a new paradigm for treating rectal cancer - but to-date, there are no predictors for this
response, and no recognised adjuvants to enhance this response.
The aim of this study is to extend an established HPV genotyping research programme, using highsensitivity assays in anal cancer (Renehan & Hampson, Manchester), to rectal cancer, with the two-fold
objectives to:
i) Describe the proportions of HPV 16, 18 and 33 in pre-treatment rectal cancer specimens, and relations
with age, gender and stage (CRUK biomarker classification: BM Discovery Stage 1), and;
ii) Test the hypothesis that HPV16 positivity is greater in patients who subsequently develop a complete
response compared with those without a complete response to CRT (CRUK biomarker classification:
BM Discovery Stage 2).
We consider these objectives as ‘proof of concept’, forming a platform for future biomarker
validation (see below).
Knowns and unknowns: (i) There is evidence of a causal association between HPV infection and rectal
cancer based on Bradford-Hill criteria of analogy, biological plausibility, strength of association, and to a
lesser extent the criteria of consistency, specificity and coherence [1]; (ii) a recent meta-analyses estimated
that HPV is present in 42% of colorectal tumours versus 6% of non-diseased normal mucosa [3]; (iii) many
of the earlier studies (reviewed in [3]) used crude methodologies (e.g. Southern blots and
immunohistochemistry of the oncoproteins) and probably underestimated prevalence; (iv) most series are
small - only four studies had greater than 100 patients
Salisbury
Manchester
[3]; (v) HPV16 appears to the dominant genotype; but
HPV18 and 33 also appear dominant in some series [3];
Rectal cancer
Rectal cancer
Database
OnCoRe d/b
Database
(vi) there is yet no consistent 'correlation' between HPV
(2006-2013)
N > 130
(2006-2013)
positivity and tumour location or stage [3]; and (vii)
there is no substantive study of HPV positivity and
Controls
Cases
Controls
Cases
+ N ≈ 10
+ N ≈30
N ≈ 70
N ≈ 50
treatment outcome.
Pathology-assisted tissue retrieval
MCRC Biobank-facilitated tissue retrieval
14. Methodology
Setting: Salisbury NHS Foundation Trust and the
Hampson laboratory (N = 160)
Tissue blocks transfer
University of Manchester (2006-2013)
Patients: Pre-treatment biopsy tissue in patients with
DNA extraction
rectal adenocarcinoma undergoing CRT.
HPV genotyping
Study design: The design is shown in the flow diagram
(Figure 1) – consists of two levels corresponding to the
Level I - objective (i)
Baseline characterisation
two objectives. Level I is a baseline characterisation
Controls
Cases
(descriptive) study; level II is a case-control study.
Level II - objective (ii)
N = 120 vs. N = 40
Controls: From both centre databases, patients with
rectal cancer who underwent CRT and subsequently
1 Project study design
proceeded to respective surgery with visible tumour Figure
OnCoRe: BDRF funded North West registry of complete responders
present (non- or partial responders) – considered the MCRC: Manchester Cancer Research Centre
‘normal’ clinical pathway – will be identified and tissue
blocks retrieved.
Cases: Patients with rectal cancer who had either a complete clinical or pathological response to CRT will
be identified from both centre databases. For Manchester, we will additionally use the OnCoRe database (a
BDRF funded project of clinical complete responders across the North West of England) to identify cases.
We will use ‘real-world’ definitions of complete responses i.e. as determined by the MDT.
Tissue transfer: Whole paraffin-embedded tissue blocks will be transferred to Manchester.
DNA extraction: DNA will be extracted from all the blocks in the NHS BRC Biobank laboratory following
GCLP QC standards. QIAamp DNA FFPE tissue kit will be used for purification of genomic DNA from
formalin-fixed, paraffin-embedded tissues. H&E staining will be performed on the slides of the first and last
cuts for each sample for pathological examination (to confirm presence of adenocarcinoma). The quality of
the DNA will be checked using polymerase chain reaction (PCR) to detect the presence of a house-keeping
gene (beta-2-microglobulin). If the quality of samples is adequate, all the DNA samples will undergo whole
2
genome amplification (WGA). The quality of the DNA will be checked again using PCR (determination of
the presence of beta-2-microglobulin).
Laboratory measurements: Multiplex PCR will be performed for all HPVs that will be done in this study.
Using two sets of primers for
M 98 99 100 101 102 103 …. 111 112 113 114 115 W1 W2 NC
each HPV genotype, higher Betamicroglobulin
sensitivity/accuracy for HPV
genotyping will be performed.
1000 bp
This approach is novel and
100 bp
increases sensitivity of each
HPV genotype. Each PCR will
be
performed
with
an HPV16
M NC 98 99 100 101 102 103 … 111 112 113 114 115 PC NC
appropriate positive control as
1000 bp
well as with negative control
that will be run at the beginning
of each PCR and at the end of
209 bp
each PCR to avoid any
148 bp
100 bp
primers
contamination (Figure 2).
neg
Planned statistical analysis:
Figure 2 Double band PCR readouts Upper panel: high-quality DNA extract confirmed.
Analyses for objective (i) will
Lower panel: example of HPV16 in anal cancer samples. This approach increases sensitivity –
be standard chi-squared tests
for example, in our laboratory, the detection rate for HPV16 in anal cancer is 89%
(e.g. proportions by gender);
Mann-Whitney tests (e.g. median age by HPV positivity); and trends across ordinal categories (e.g.
proportions by stage).
For objective (ii), we will use logistic regression to test differences between complete responders versus
others, allowing for adjustment for potential confounders identified in the baseline analysis.
Power calculations: We stipulate from the outset that to demonstrate ‘proof of concept’ the minimal odds
ratio is 3.0. Based on deliverable tissue retrieval in the timeframe and clinical practices of the two centres,
the control sample size = 120. The estimated cases sample size = 40 i.e. a 1:3 case-control design. We
estimate the HPV16 positivity among responders will be 69%; and among non-responders will be 36%
(chosen to achieve an odds ratio of 4, and population prevalence of HPV16 positivity of 42%). The power at
these sample sizes to show this difference is 95% (sampsi command in STATA).
In a worst-case scenario analyses, if we only retrieve and extract high-quality DNA in 30 cases (complete
responders), the power to show difference is 88%. If the HPV positivity in the responders arm were only
63% (odds ratio = 3) the power to show difference is 80%.
Existing Infrastructure: Manchester – the Manchester Cancer Research Centre (MCRC) Biobank will
retrieve the targeted archival tissues. An already funded biobank technician (through the Christie Surgical
Oncology Research Group – lead: Renehan) will facilitate this. DNA will be extracted through the
Manchester Central Biobank (site of Hampson laboratory) using existing protocols. The HPV detection
work will be performed by a project-dedicated post-doctoral scientist experienced in these techniques, the
Hampson laboratory, a leading Viral Oncology laboratory.
Salisbury – targeted archival tissue will be retrieved through the Pathology Department (Fuller). Clinical
data will be taken from existing NBOCAP-compliant databases at both centres.
Data/tissue transfer agreements have been commonly used between Manchester and other UK centres.
Ethics: A strength of this study is the MCRC Biobank existing ethics – this allows tissue retrieval from
clinical archives without need for individual patient retrospective consent (see supporting letter). The
‘Salisbury arm’ of the proposal will be suitable for proportionate ethics review, reducing delays.
Platform for future research: If our hypothesis is upheld, two research directions will emerge:
1. Biomarker validation i.e. retrospective 2x2 interactive (predictive) analysis of HPV positivity versus
HPV negativity in patients within a prospective trial of CRT versus no CRT;
2. Development of adjuvants to enhance radiosensitivity – ultimately reducing treatment-related toxicity.
Examples include: (i) engineering HPV oncoproteins into HPV-negative HNC cells; and (ii) AKT
inhibition (e.g. nelfinavir) specifically enhances radiosensitvity in HPV positive tumours (based on
oropharyngeal cancer studies) [4].
3
5. References (if any): Maximum of 4
1. Burnett-Hartman AN, Newcomb PA, Potter JD (2008) Infectious agents and colorectal cancer: a review
of Helicobacter pylori, Streptococcus bovis, JC virus, and human papillomavirus. Cancer Epidemiol
Biomarkers Prev 17: 2970-2979.
2. O'Rorke MA, Ellison MV, Murray LJ, Moran M, James J, et al. (2012) Human papillomavirus related
head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 48: 1191-1201.
3. Lorenzon L, Ferri M, Pilozzi E, Torrisi MR, Ziparo V, et al. (2011) Human papillomavirus and colorectal
cancer: evidences and pitfalls of published literature. Int J Colorectal Dis 26: 135-142.
4. Lui VW, Grandis JR (2012) Primary chemotherapy and radiation as a treatment strategy for HPV-positive
oropharyngeal cancer. Head Neck Pathol 6 Suppl 1: S91-97.
16. Sample size and source of statistical
advice (if appropriate)
Controls = 120; cases = 40. Total = 160
Power calculations in main text.
17. Have you applied for or acquired funding
from any other sources(s)?
Yes
If Yes, where?
No 
Lay summary (200-300 word summary)
Problem addressed, back ground and strategic significance: Large bowel cancer is a major cause of
death worldwide. The cause of non-genetic cancer is poorly understood with a number of potential causative
agents. Recent evidence suggests that high-risk human papillomavirus (HPV) can be identified in >40% of
large bowel cancer tissue compared with 6% of tissues from normal patients. Further evidence suggests i)
HPV is more likely to be found in tumours of the rectum rather than the colon ii) HPV is associated with
less advanced disease. HPV is also associated with other cancers especially of the throat and in these
patients is associated with improved responses to radiotherapy and improved survival.
Methods: HPV genotyping will be performed on rectal cancer specimens from 2 centres (Manchester and
Salisbury). Funding will support tissue collection, DNA extraction and HPV genotyping to identify 3 HPV
genotypes
Results of this research: We hope to confirm that high risk HPV can be identified in a proportion of
patients with rectal cancer and compare whether patients with HPV positive rectal cancers respond better to
radiotherapy and whetehr this impacts on recurrence and survival..
Changes to the current position: This study may add to the body of evidence that HPV is associated with
rectal cancer and identify whether HPV positive tumours respond better to radiotherapy.
4
NAME
Graham William Branagan
TELEPHONE
E-MAIL
D.O.B.
19.11.68
GMC No.
4105260
HOSPITAL
Salisbury Foundation Trust (SFT)
POST
Consultant Colorectal Surgeon
[email protected]
RESEARCH
Master of Surgery, University of Portsmouth July 2002.
PI for the Mercury II low rectal cancer study
PI for DREAMS
PI for LARS
PI for ISAAC
Past member of the Research and Audit Committee of the ACPGBI.
Past member of the NCRI anal cancer subgroup.
Reviewer for Digestive Diseases, BJS, Surgical Oncology, Colorectal Disease and the Annals of the Royal
College of Surgeons, Annals of Surgery, Diseases of the Colon and Rectum and the international Journal of
Urology .
Publications: One book chapter, two invited articles, twenty-three peer-reviewed articles.
Presentations: Five invited lectures, 13 oral presentations (international / national).
MOST RECENT PUBLICATIONS
Barker T, Branagan G, Wright E, Crick A, McGuiness C, Chave H. Vertical rectus abdominis
myocutaneous flap reconstruction of the perineal defect after abdominoperineal excision is associated with
low morbidity. Colorectal Dis. 2013 May 15. doi: 10.1111/codi.12286. [Epub ahead of print]
Byrne BE, Branagan G, Chave HS. Unselected rectal cancer patients undergoing low anterior resection
with defunctioning ileostomy can be safely managed within an Enhanced Recovery Programme. Tech
Coloproctol. 2013 Feb;17(1):73-8.
Foster JD, Pathak S, Smart NJ, Branagan G, Longman RJ, Thomas MG, Francis N. Reconstruction of the
perineum following extralevator abdominoperineal excision for carcinoma of the lower rectum: a systematic
review. Colorectal Dis. 2012 Sep;14(9):1052-9
Dabbas N, Adams K, Chave H, Branagan G. Current practice in abdominoperineal resection: an email
survey of the membership of the Association of Coloproctology. Ann R Coll Surg Engl. 2012
Apr;94(3):173-6
How P, Stelzner S, Branagan G, Bundy K, Chandrakumaran K, Heald RJ, Moran B. Comparative quality
of life in patients following abdominoperineal excision and low anterior resection for low rectal cancer. Dis
Colon Rectum. 2012 Apr;55(4):400-6
5
CURRICULUM VITAE
Surname
Fuller
Forename(s)
Clare Elizabeth
Work address:
Salisbury District Hospital
Salisbury
Wiltshire
SP2 8BJ UK
Telephone No: 01722 429001
Fax No: 01722 341499
E-mail address: [email protected]
GMC registration no: 3091894
Qualifications:
BM BCh MA FRCPath
Present Post
Consultant Histopathologist 1994-present
Previous appointments:
Lecturer Pathology Sheffield Medical School 1990-1994
Clinical research experience:
Recently Mecury II and BACCHUS, supplying blocks, slides and reports for multicentre
national studies
Clinical research training (eg, ICH GCP/EU Directive etc) including date of course
attended:
None
Signed:Clare Fuller
Dated:30.07.2013
6
Andrew Renehan PhD FRCS FRCS(Gen Surg)
Current post: Professor in Cancer Studies and Surgery and Honorary Consultant Colorectal Surgeon,
Peritoneal Tumour Service at the Department of Surgery, the Christie NHS Foundation Trust, Manchester.
Academic affiliation: Faculty Institute of Cancer Sciences, University of Manchester
I work a split 50: 50 clinical: academic biweekly job plan.
Tel (W): 0161 446 3157
e-mail: [email protected]
Prestigious award: Hunterian Professor 2011/2012
Research / Editorial roles:
STROBE reporting revision group/COSMOS writing group
Diabetes & Research Cancer Consortium
NICE Colorectal Cancer Guidelines Development group
ACPGBI Research & Audit Committee
NCRN ano-rectal trials subgroup
COLOFOL steering committee– European trial in colorectal cancer follow-up
Dutch CEA follow-up in colorectal cancer trial advisory group
Member of editorial board: Cochrane Collaboration Colorectal Cancer Group
Member of editorial board: British Journal of Surgery
Lead cancer & obesity research group, Manchester CRC & MRC Health eResearch Centre
Grants awarded: last 2 years
2011: Novo Nordisk Independent research award £50,000
2011-2013: NAEDI Cancer screening in type 2 diabetes £122,000
2012-2014: NORD/Christie charitable funds £103,000
2012-2013: Sanofi-Pasteur MPS Independent research award £30,000
2013-2014: WCRF global attributable risk of BMI to cancer incidence - £500,000 (Co-investigator)
2013-2015: Pancreatic Cancer UK £74,000
2013-2015: Bowel Disease Research Foundation £94,000
2013-2018: MRC Health eResearch Centre - £5.5M (Co-investigator)
LIST OF KEY PUBLICATIONS (SELECTED SINCE 2012)
1. McDonald JR, O'Dwyer ST, Rout S, Chakrabarty B, Sikand K, Fulford PE, et al. Classification of and
cytoreductive surgery for low-grade appendiceal mucinous neoplasms. Br J Surg 2012;99(7):987-92.
2. Renehan AG. Insulin analogues and cancer risk: the emergence of second-generation studies.
Diabetologia 2012;55(1):7-9.
3. Renehan AG, Flood A, Adams KF, Olden M, Hollenbeck AR, Cross AJ, et al. Body Mass Index at
Different Adult Ages, Weight Change, and Colorectal Cancer Risk in the National Institutes of
Health-AARP Cohort. Am J Epidemiol 2012.
4. Renehan AG, M Z, Egger M. Obesity and cancer risk: seeking new mechanistic insights from
epidemiology [commissioned]. Nature Reviews Cancer 2012.
5. Renehan AG, Solomon M, Zwahlen M, Morjaria R, Whatmore A, Audi L, et al. Growth hormone
receptor polymorphism and growth hormone therapy response in children: a Bayesian meta-analysis.
Am J Epidemiol 2012;175(9):867-77.
6. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H. Diabetes and cancer (2): evaluating the
impact of diabetes on mortality in patients with cancer. Diabetologia 2012.
7. Parkin E, O’Reilly DA, Adam R, Kaiser GM, Laurent C, Elias E, et al. The effect of hepatic steatosis on
survival following resection of colorectal liver metastases in patients without pre-operative
chemotherapy [in press] DOI:10.1111/hpb.12007. HPB 2013.
8.. Sperrin M, Marshall AD, Higgins V, Buchan IE, Renehan AG. Levelling off of adult body mass index
trends in England: a latent class analysis of cross-sectional surveys (1992-2009). PLoS Medicine
2013.
7
Curriculum Vitae
Dr Ian N. Hampson
Date of birth: 26th February, 1954
Degrees: 1974-1977 BSc. Hon, Bio Sci, University of Lancaster
1978-1982 PhD. Faculty of Medicine, PICR, Christie Hospital, Manchester, UK.
Posts Held:
Past 1982-1985 Post Doctoral Research Fellow, Clinical Research,
Christie Hospital, Manchester, UK.
1985-1997 Grade I Post Doctoral Scientist, Department of Experimental Haematology, Paterson Institute
for Cancer Research, Christie Hospital, Manchester, UK.
Present; July1997 Reader in Viral Oncology, Inst of Cancer Sciences, University of Manchester, St.
Mary’s Hospital, Oxford Road, Manchester M13 9WL.
Contact Details; Telephone 016 1 701 6938, Mobile 07500900871
e-mail [email protected]
Recent Peer-Reviewed Publications
Maranga IO, Hampson L, Oliver AW, He X, Gichangi P, Rana F, Opiyo A, Hampson IN. HIV Infection
Alters the Spectrum of HPV Subtypes Found in Cervical Smears and Carcinomas from Kenyan Women.
Open Virol J. 2013;7:19-27..
Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, Kitchener HC, Einstein
MH. Therapy of human papillomavirus-related disease. Vaccine. 2012 Nov 20;30 Suppl 5:F71-82.
He X, Walker TD, Maranga IO, Oliver AW, Hampson L, Hampson IN. No biological evidence of
XMRV infection in cervical smears from HIV/ HPV positive and negative Kenyan women. PLoS One.
2012;7(10):e47208.
Shalaby MA, Hampson L, Oliver A, Hampson I. Plexin D1: new potential biomarker for cervical
cancer. J Immunoassay Immunochem. 2012;33(3):223
Hampson IN, Oliver AW, Hampson L. Targeting activated Rho proteins: a new approach for treatment
of HPV and other virus-related cancers? Expert Rev Anticancer Ther. 2011; Jul;11(7):975-8. (Invited
Editorial)
Batman G, Oliver AW, Zehbe I, Richard C, Hampson L, Hampson IN. Lopinavir up-regulates
expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma
cells. Antivir Ther. 2011;16(4):515-25
Zehbe I, Richard C, Lee KF, Campbell M, Hampson L, Hampson IN. Lopinavir shows greater
specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related
lesions. Antiviral Res. 2011 Aug;91(2):161-6
Oliver AW, He X, Borthwick K, Donne AJ, Hampson L, Hampson IN. The HPV16 E6 binding protein
Tip-1 interacts with ARHGEF16, which activates Cdc42. Br J Cancer. 2011; Jan 18;104(2):324-31
Kim DH, Jarvis RM, Allwood JW, Batman G, Moore RE, Marsden-Edwards E, Hampson L, Hampson
IN, Goodacre R. Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16
E6 expressing cervical carcinoma cells. Anal Bioanal Chem. 2010 Dec;398(7-8):3051-61.
8
Dr Ivona Baricevic-Jones
Date of birth:
23/10/1971 (Belgrade, Serbia)
Telephone:
0161 4855603, mobile 07999515895
Electronic mail:
[email protected] and [email protected]
Degrees:
1990-1995
Biochemistry BSc First Class (honours). Department of Biochemistry, Faculty of
Chemistry, University of Belgrade, Belgrade, Serbia.
1995-1999
Biochemistry MSc (by research). INEP and Department of Biochemistry, Faculty of
Chemistry, University of Belgrade, Belgrade, Serbia
2001-2004
Biochemistry PhD. INEP and Department of Biochemistry, Faculty of Chemistry,
University of Belgrade, Belgrade, Serbia.
Posts Held:
2004-2009
Postdoctoral researcher at the Institute for the Application of Nuclear Energy (INEP)
belonging to the University of Belgrade, Belgrade, Serbia.
2009-2012
Postdoctoral researcher at the Paterson Institute for Cancer Reasearch, (Department
of Clinical and Experimental Pharmacology), University of Manchester, Manchester,
UK. Supervisor: Dr. Andrew Renehan.
2012-present
Postdoctoral researcher at Viral Oncology laboratory at St Mary’s Hospital,
University of Manchester, Manchester, UK. Supervisor: Dr. Andrew Renehan and Dr.
Ian Hampson.
Recent Peer-Reviewed Publications:
Baričević I, Roberts D & Renehan A (2013). Chronic insulin exposure does not cause insulin-resistance but
is associated with chemo-resistance in colon cancer cells. Manuscript submitted to Hormone Metabolic
Research.
Baričević I, Masnikosa R, Lagundžin D, Golubović V & Nedić O (2010) Alterations of insulin-like growth
factor binding protein 3 (IGFBP-3) glycosylation in patients with breast tumours. Clin Biochem 43, 725731.
Masnikosa R, Baričević I, Lagundžin D & Nedić O (2010) Characterisation of N-glycans bound to IGFBP3 in sera from healthy adults. Biochimie 92(1), 97-101.
Ćujić D, Golubović S, Bojić-Trbojević Ž, Ilić N, Baričević I & Nedić O (2010). Differential diagnosis of
liver diseases using serum biomarkers. Journal of BUON 15, 141-146.
Masnikosa R, Baričević I, Lagundžin D & Nedić O (2010) Detection of insulin-like growth factor binding
proteins (IGFBPs) in porcine serum. Acta Veterinaria (Beograd) 60 (4), 327-337.
Nedić O, Malenković V, Dukanović & Baričević I (2008) Association of elevated IGFBP-1 with increased
IGF-II concentration in patients with carcinoma of the liver. Int J Biol Markers 23 (4), 225-230.
Kirovski D, Lazarević M, Baričević-Jones I, Nedić O, Masnikosa R & Nikolić JA (2008) Effects of peroral
insulin and glucose on circulating insulin-like growth factor-I (IGF-I), its binding proteins and thyroid
hormones in neonatal calves. Can. J. Vet. Res. 72 (3), 253-258.
9
Curriculum Vitae: Dr Matthew Sperrin
General Information
Employment History
 Lecturer in Health Data Science, Centre for Health Informatics, Institute of Population Health, May
2013 - Present
 Lecturer in Statistics, Lancaster University, Jan 2011 – Apr 2013
 Statistician, Northwest Institute for Biohealth Informatics, University of Manchester, Jan 2010 – Dec
2010
Academic/Professional Qualifications
 Ph.D. in Statistics, Lancaster University, 2010
o Title: Statistical Methodology Motivated by Problems in Genetics; Supervisor : Dr Thomas Jaki
 MMORSE, Master of Maths, Operational Research, Statistics and Economics, University of Warwick,
2006, First Class Honours
 GradStat (Graduate Statistician Status), Royal Statistical Society, 2010 – Present
 Higher Education Academy, Fellow since 2012
Research
The focus of my research is maximising the potential of available data to improve healthcare. I am
interested in developing principled statistical methodology that can be applied to provide improved decision
support in health and medicine. This can be decisions on a micro-level, such as what treatments are best for
an individual patient, or on a strategic level, such as understanding the potential health impact of
population-level interventions.
Recent Funded Projects
 Co-Investigator (PI: Thomas Jaki), Towards full use of available data to improve clinical outcome
prediction, National Institute for Health Research (NIHR), Oct 2013 - Sept 2014, £30,000.
 Co-Investigator (PI: Andrew Renehan), PanORAMA project: Pancreatic Cancer Predisposition,
Obesity-Related Deposition Assessment using Magnetic Resonance ImAging: a development and
discovery study to evaluate the assessment of pancreatic fat deposition using MR imaging as a
predisposition biomarker for pancreatic cancer, Cancer Research UK, Aug 2013 – Jul 2014, £75,000.
 Co-Investigator (PI: Iain Buchan), Health e-Research Centre (HeRC), Medical Research Council
(MRC), Mar 2013 - Feb 2018, £4,500,000.
 Management of food allergens: from threshold doses to analysis in food, Food Standards Agency (PI:
Clare Mills), Feb 2012 – Jan 2013.
 Optimal and pragmatic designs for pre-clinical studies to detect interaction between two compounds: a
simulation study, Funded by AstraZeneca through the Medical and Pharmaceutical Research Unit (PI:
Prof Anne Whitehead), Jan 2011-Dec 2011.
10